# OnCo record paper-nct06747338-jama-oncol-2026 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-nct06747338-jama-oncol-2026/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-nct06747338-jama-oncol-2026" ;
  schema:name "Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial"@en ;
  schema:description "Published report from the trial registered as NCT06747338, in JAMA Oncology (2026), chosen as the most cited paper whose own text cites the registry id."@en ;
  schema:url <https://onco.cc/key-papers/paper-nct06747338-jama-oncol-2026/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1001/jamaoncol.2026.3329>, <https://pubmed.ncbi.nlm.nih.gov/42690668/>, <https://europepmc.org/article/MED/42690668>, <https://clinicaltrials.gov/study/NCT06747338> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1001/jamaoncol.2026.3329> ;
  schema:datePublished "2026"^^xsd:gYear ;
  schema:author "Li J, Liu T, Yu KD, et al." ;
  onco:trials <https://onco.cc/trials/nct06747338/> ;
  onco:journals <https://onco.cc/journals/jama-oncology/> .